$2.02
0.98% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
CA00288U1066
Symbol
ABCL
Sector
Industry

AbCellera Biologics Inc Target price 2025 - Analyst rating & recommendation

AbCellera Biologics Inc Classifications & Recommendation:

Buy
89%
Hold
11%

AbCellera Biologics Inc Price Target

Target Price $8.43
Price $2.02
Potential
Number of Estimates 7
7 Analysts have issued a price target AbCellera Biologics Inc 2026 . The average AbCellera Biologics Inc target price is $8.43. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 8 Analysts recommend AbCellera Biologics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the AbCellera Biologics Inc stock has an average upside potential 2026 of . Most analysts recommend the AbCellera Biologics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 28.83 26.06
24.19% 9.60%
EBITDA Margin -776.69% -900.42%
38.80% 15.93%
Net Margin -564.90% -762.41%
46.74% 34.96%

10 Analysts have issued a sales forecast AbCellera Biologics Inc 2025 . The average AbCellera Biologics Inc sales estimate is

$26.1m
Unlock
. This is
12.73% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$68.7m 197.30%
Unlock
, the lowest is
$16.0m 30.67%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $28.8m 24.19%
2025
$26.1m 9.60%
Unlock
2026
$52.2m 100.37%
Unlock
2027
$77.7m 48.71%
Unlock
2028
$144m 85.44%
Unlock
2029
$204m 41.46%
Unlock

3 Analysts have issued an AbCellera Biologics Inc EBITDA forecast 2025. The average AbCellera Biologics Inc EBITDA estimate is

$-235m
Unlock
. This is
1.50% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-213m 7.79%
Unlock
, the lowest is
$-248m 7.08%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-224m 5.22%
2025
$-235m 4.80%
Unlock
2026
$-240m 2.41%
Unlock
2027
$-277m 15.13%
Unlock

EBITDA Margin

2024 -776.69% 38.80%
2025
-900.42% 15.93%
Unlock
2026
-460.22% 48.89%
Unlock
2027
-356.30% 22.58%
Unlock

5 AbCellera Biologics Inc Analysts have issued a net profit forecast 2025. The average AbCellera Biologics Inc net profit estimate is

$-199m
Unlock
. This is
18.37% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-173m 3.09%
Unlock
, the lowest is
$-221m 31.52%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-163m 11.24%
2025
$-199m 22.01%
Unlock
2026
$-183m 8.03%
Unlock
2027
$-179m 2.04%
Unlock
2028
$-148m 17.22%
Unlock
2029
$-104m 29.53%
Unlock

Net Margin

2024 -564.90% 46.74%
2025
-762.41% 34.96%
Unlock
2026
-349.94% 54.10%
Unlock
2027
-230.52% 34.13%
Unlock
2028
-102.90% 55.36%
Unlock
2029
-51.26% 50.18%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.55 -0.67
7.84% 21.82%
P/E negative
EV/Sales negative

5 Analysts have issued a AbCellera Biologics Inc forecast for earnings per share. The average AbCellera Biologics Inc EPS is

$-0.67
Unlock
. This is
17.54% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.58 1.75%
Unlock
, the lowest is
$-0.74 29.82%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.55 7.84%
2025
$-0.67 21.82%
Unlock
2026
$-0.61 8.96%
Unlock
2027
$-0.60 1.64%
Unlock
2028
$-0.50 16.67%
Unlock
2029
$-0.35 30.00%
Unlock

P/E ratio

Current -3.54 53.05%
2025
-3.03 14.50%
Unlock
2026
-3.30 8.91%
Unlock
2027
-3.37 2.12%
Unlock
2028
-4.07 20.77%
Unlock
2029
-5.77 41.77%
Unlock

Based on analysts' sales estimates for 2025, the AbCellera Biologics Inc stock is valued at an EV/Sales of

-0.09
Unlock
and an P/S ratio of
23.13
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -0.10 100.83%
2025
-0.09 10.60%
Unlock
2026
-0.04 50.11%
Unlock
2027
-0.03 32.74%
Unlock
2028
-0.02 46.00%
Unlock
2029
-0.01 29.63%
Unlock

P/S ratio

Current 26.08 17.46%
2025
23.13 11.29%
Unlock
2026
11.55 50.09%
Unlock
2027
7.76 32.75%
Unlock
2028
4.19 46.08%
Unlock
2029
2.96 29.31%
Unlock

Current AbCellera Biologics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Truist Securities
Locked
Locked
Locked May 16 2025
Keybanc
Locked
Locked
Locked Apr 16 2025
Benchmark
Locked
Locked
Locked Mar 03 2025
Stifel
Locked
Locked
Locked Feb 28 2025
Keybanc
Locked
Locked
Locked Jan 08 2025
Benchmark
Locked
Locked
Locked Nov 05 2024
Stifel
Locked
Locked
Locked Nov 05 2024
Analyst Rating Date
Locked
Truist Securities:
Locked
Locked
May 16 2025
Locked
Keybanc:
Locked
Locked
Apr 16 2025
Locked
Benchmark:
Locked
Locked
Mar 03 2025
Locked
Stifel:
Locked
Locked
Feb 28 2025
Locked
Keybanc:
Locked
Locked
Jan 08 2025
Locked
Benchmark:
Locked
Locked
Nov 05 2024
Locked
Stifel:
Locked
Locked
Nov 05 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today